Asia Mixed on New Tariff Proposals
Asia-Pacific stocks traded mixed Wednesday after U.S. President Donald Trump proposed tariffs “in the neighborhood of 25%” on autos, semiconductors and pharmaceutical imports.In Japan, the Nikkei 225 index dipped 105.79 points, or 0.3%, to 39,164.61. The country had reported a two-year high trade deficit.In Hong Kong, the Hang Seng index dropped 32.57 points, or 0.1%, to 22,944.24. Business sentiment for Japanese manufacturers rose for the second month in February, results from the Reuters Tankan poll indicates. The manufacturers’ sentiment index rose to plus 3 — its highest level since November — from plus 2 in January.Australian markets lost strength a day after the country’s central bank cut rates by 25 basis points to 4.10%, marking its first easing since November 2020.The Reserve Bank of New Zealand cut rates by 50 basis points to 3.75% in its policy meeting, in line with Reuters’ estimates. The marks the central bank’s fourth straight cut and comes as its economy slows.In other marketsThe CSI 300 in mainland China regained 27.38 points, or 0.7% to 3,940.16In Taiwan, the Taiex index shed 62.03 points, or 0.3%, to 23,604.08.In Singapore, the Straits Times index took on 8.48 points, or 0.2%, to 3,934.04In Korea, the Kospi index jumped 44.71 points, or 1.7%, to 2,671.52.In New Zealand, the NZX 50 faded 17.76 points, or 0.1%, to 13,033.36In Australia, the ASX 200 surrendered 61.82 points, or 0.7%, to 8,419.19.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


